Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors-Reference-Cited by-同舟云学术

Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors

Published:2017-01-09 Issue:3 Volume:12 Page:207-213
ISSN:1860-7179
Container-title:ChemMedChem
language:en
Short-container-title:ChemMedChem

Author:

McIver Andrew L.¹²,Zhang Weihe¹³,Liu Qingyang¹⁴,Jiang Xinpeng¹⁵,Stashko Michael A.¹,Nichols James⁶,Miley Michael J.⁷,Norris-Drouin Jacqueline¹,Machius Mischa⁷,DeRyckere Deborah⁸,Wood Edgar⁶,Graham Douglas K.⁶⁸,Earp H. Shelton⁶⁷⁹,Kireev Dmitri¹,Frye Stephen V.¹⁶⁹,Wang Xiaodong¹^ORCID

Affiliation:

1. Center for Integrative Chemical Biology and Drug Discovery; Division of Chemical Biology and Medicinal Chemistry; Eshelman School of Pharmacy, University of North Carolina at Chapel Hill; Chapel Hill NC 27599 USA

2. Present address: Chimerix. Inc.; 2505 Meridian Parkway, Suite 100 Durham NC 27713 USA

3. Present address: BioCryst Pharmaceuticals, Inc.; 2100 Riverchase Center, Building 200, Suite 200 Birmingham AL 35244 USA

4. Present address: Department of Chemistry; Montgomery College; 51 Mannakee Street Rockville MD 20850 USA

5. Present address: School of Pharmacy; Zhejiang University of Technology; Jiangshan Zhejiang China

6. Meryx, Inc.; 450 West Drive, CB# 7295 Chapel Hill NC 27599-7295 USA

7. Department of Pharmacology; University of North Carolina at Chapel Hill; Chapel Hill NC 27599-7365 USA

8. Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta; Department of Pediatrics; School of Medicine; Emory University; Atlanta GA 30322 USA

9. Lineberger Comprehensive Cancer Center; Department of Medicine; School of Medicine; University of North Carolina at Chapel Hill; Chapel Hill NC 27599 USA

Publisher

Wiley

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics,Molecular Medicine,Drug Discovery,Biochemistry,Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cmdc.201600589/fullpdf

Reference20 articles.

1. Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?

2. Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor

3. Synthesis of P1′-Functionalized Macrocyclic Transition-State Mimicking HIV-1 Protease Inhibitors Encompassing a Tertiary Alcohol

4. Tools and rules for macrocycles

5. Design, Synthesis, and Anaplastic Lymphoma Kinase (ALK) Inhibitory Activity for a Novel Series of 2,4,8,22-Tetraazatetracyclo[14.3.1.13,7.19,13]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene Macrocycles

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors;Journal of Medicinal Chemistry;2024-04-01

2. Macrocycles and macrocyclization in anticancer drug discovery: Important pieces of the puzzle;European Journal of Medicinal Chemistry;2024-03

3. Design and Activity Evaluation of Small Molecule Tyrosine Kinase Inhibitors Bearing Cyclic Polyamines;2024

4. Virtual screening of natural product as TAM family of RTK inhibitor;Nanotechnology and In Silico Tools;2024

5. Rigid Scaffolds Are Promising for Designing Macrocyclic Kinase Inhibitors;ACS Pharmacology & Translational Science;2023-07-07